医药研发需求复苏，带动CXO行业景气度提升 智通财经APP获悉，招银国际发布研报称，MSCI中国医疗指数2025年初至今（11月21日）累计上涨 62.8%，跑赢MSCI中国指数32.2%。近期，医药板块有所回调（MSCI中国医疗指数10月初至11月21日 回调8%），认为主要是由于投资人在年底进行获利了结，以及部分创新药企业的估值和BD预期较高， BD交易落地后不及预期的影响。预期在行业估值已经大幅修复的基础上，2026年医药行业较难出现普 涨的机会，然而部分个股存在估值和业绩修复的机会，例如医疗服务、制药、CXO等个股。 招银国际主要观点如下： 创新药出海BD交易爆发，管线推进将带来更大价值增量 截至2025年10月底，中国创新药出海license-out交易披露首付款达到63亿美元（+53%YoY），已超2024 全年。MNC对中国创新管线关注升温，据医药魔方，2025年前9个月，TOPMNC的中国引进交易数量/ 金额占比达20%/39%。同时，MNC现金流仍旧充裕，截至3Q25，TOPMNC的平均在手现金为108亿美 元，并且有充足的自由现金流，足以支撑持续并购或资产引进。展望2026年，该行认为，中 ...

E-commerce Sector - The e-commerce sector saw a strong performance with a near 3% increase in the index, driven by stocks like RuYuchen, YiWanYiChuang, and QingMuKeJi [2] - The "Double Eleven" shopping festival has officially started, with major platforms like Taobao and Tmall launching their promotions, following JD's early start [3] - Online retail sales in China from January to August increased by 9.6%, with significant growth in digital products such as smart wearables and computers, which grew by 25.2% and 23.7% respectively [4] Pharmaceutical Sector - The pharmaceutical and biotech sector experienced a collective surge, particularly in innovative drugs, with the index rising over 2% [7] - Companies like Asia Pacific Pharmaceutical and Guangsheng Tang saw significant stock price increases, with some stocks hitting the daily limit [7] - The IPO market for innovative drugs is heating up, with a focus on cutting-edge fields such as small molecule drugs and antibody-drug conjugates [9] Cross-border E-commerce - Cross-border e-commerce is rapidly expanding, with sales of Indonesian bird's nest and Kazakh safflower oil increasing by 160.1% and 143.2% respectively from January to August [6] - The growth in e-commerce promotions is expected to release potential consumer demand, benefiting shelf e-commerce [6] New Listings - XuanZhu Bio debuted on the Hong Kong Stock Exchange, initially surging over 167% before stabilizing at a still significant increase of over 130% [10][11] - XuanZhu Bio focuses on "digestion + oncology" and is also entering the NASH market, which currently lacks approved therapies in China, indicating a large unmet need [12] Market Trends - The overall A-share market showed slight fluctuations, with major indices experiencing mixed results, but the number of rising stocks outnumbered those that fell [5] - The innovative drug sector is expected to see a transformation driven by business development (BD) opportunities and new product launches, with a record 95 BD transactions in China's innovative drug sector since 2025 [12]

Market Performance - The Hang Seng Healthcare Index increased by 2.69% as of September 5, 2025, with notable gains from stocks such as Eucan Vision Bio-B (+13.93%), 3SBio (+11.67%), and CanSino-B (+10.58%) [3] - The Hang Seng Healthcare ETF (513060) rose by 2.36%, closing at 0.74 CNY, and has seen a 5.57% increase over the past week [3] - The Hang Seng Innovation Drug Selection Index surged by 3.33%, with 3SBio and CanSino-B also showing significant increases [5] - The Innovation Drug Selection ETF (520690) increased by 2.61%, reaching 1.06 CNY, and has recorded a 6.60% rise over the past week [5] Liquidity and Trading Activity - The Hang Seng Healthcare ETF had a turnover rate of 25.37% with a trading volume of 1.917 billion CNY, indicating active market participation [3] - The average daily trading volume for the Hang Seng Healthcare ETF over the past week was 3.088 billion CNY, ranking it first among comparable funds [3] - The Innovation Drug Selection ETF had a turnover rate of 34.1% with a trading volume of 124 million CNY, also reflecting active trading [5] - The average daily trading volume for the Innovation Drug Selection ETF over the past week was 237 million CNY [5] New Drug Developments - A new pediatric influenza treatment, the Mavirovir granules, developed by Xiansheng Pharmaceutical and Antikang Bio, has had its market application accepted, targeting children aged 2-11 [6] - The HRS-4729 injection by Heng Rui Pharmaceutical has received clinical trial approval, aiming to be a first-in-class triple receptor agonist for weight loss and liver fat reduction [6][7] Institutional Insights - The introduction of the first domestic pediatric influenza drug is expected to address the seasonal demand for pediatric medications, potentially boosting sentiment in the anti-infection and pediatric channels [7] - The clinical approval of Heng Rui's triple receptor agonist is anticipated to enhance the long-term outlook for local companies in the GLP-1 expansion mechanism, increasing interest in related CRO/CDMO and metabolic pipeline companies [7][8] ETF Overview - The Hang Seng Healthcare ETF has a current size of 7.463 billion CNY, ranking it among the top third of comparable funds [10] - The ETF closely tracks the Hang Seng Healthcare Index, which reflects the performance of healthcare-related securities listed in Hong Kong [10] - The top ten weighted stocks in the Hang Seng Healthcare Index account for 62.87% of the index, including companies like BeiGene and Innovent Biologics [10] - The Innovation Drug Selection Index also has a significant concentration, with its top ten stocks representing 78.87% of the index [10]